Overview
HIMS market data
Price History
HIMS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- 58.82 P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.34 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -0.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.74 – $70.43 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $28.42 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Alpha Vantage OVERVIEW · market cap $7.3B · P/B 16.98 · P/S 3.09.
Company news
Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $27Benzinga · Jul 24, 2026, 6:02 PM
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the SpotlightBenzinga · Jul 24, 2026, 12:15 PM
QUICK SPARK: Martin Shkreli Shorts Hims & Hers Stock, Says 'Peptides Are Fake Medicine'Benzinga · Jul 23, 2026, 7:15 PM
Citigroup Maintains Neutral on Hims & Hers Health, Raises Price Target to $35Benzinga · Jul 23, 2026, 7:05 PM
Why Is Hims & Hers Health Stock Surging on Thursday?Benzinga · Jul 23, 2026, 6:34 PM
Hims & Hers Health shares are trading higher after an FDA advisory panel voted to place BPC-157 peptide on an allowed pharmacy compounding list.Benzinga · Jul 23, 2026, 5:01 PM
FDA Advisory Panel Votes To Place BPC-157 Peptide On Allowed Pharmacy Compounding ListBenzinga · Jul 23, 2026, 4:53 PM
'Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails' - BloombergBenzinga · Jul 23, 2026, 2:14 PM
Novo Nordisk Takes Legal Action Against Eli Lilly To Stop Multiple Misleading National GLP-1 Advertising CampaignsBenzinga · Jul 21, 2026, 11:42 AM
8-K filing — Hims & Hers Health, Inc. (HIMS)SEC EDGAR · Jul 17, 2026, 8:13 PM